RxDoctor Payments Data

Vineet Gupta, MD

Family Medicine · Yuba City, CANPI 1598806390

Payments from drug & device makers

$275in general payments, 2019–2025

Across 7 payments — averaging $39.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$121
  • Intuitive Surgical$100
  • GSK$23
  • Pfizer$17
  • Radius Health, Inc.$14

What the payments were for

  • Food & beverage$25894%
  • Education$176%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson2$121
Intuitive Surgical1$100
GSK2$23
Pfizer1$17
Radius Health, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$275 in reported general payments places this provider in the 50th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$265,582
Medicare patients
251
Services billed
3,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin121$117,061
OzempicSemaglutide59$78,595
JanuviaSitagliptin Phosphate71$72,909
EliquisApixaban71$66,509
ProliaDenosumab18$29,042
FarxigaDapagliflozin Propanediol30$26,833
TrulicityDulaglutide12$24,086
Fiasp FlextouchInsulin Aspart (Niacinamide)17$19,313
MyrbetriqMirabegron29$18,214
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$17,601
Tresiba Flextouch U-200Insulin Degludec24$15,899
Tresiba Flextouch U-100Insulin Degludec25$11,896
LinzessLinaclotide13$10,740
VeozahFezolinetant15$9,937
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$9,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$66,50971 claims
GSKTrelegy Ellipta, Anoro Ellipta$23$24,96347 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 10,533 family medicine providers in California.

Other family medicine in Yuba City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →